Clinical trials: Waldenstroms Macroglobulinaemia
Waldenstrom Macroglobulinemia, Waldenstrom's Disease
Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia
This study evaluates the safety and efficacy of daratumumab in combination with ibrutinib in patients with Waldenstrӧm's macroglobulinemia (WM). The study will evaluate this combination in two cohorts.
- Conditions
- Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent
- Trial name
- NCT03679624
- Testing
- Ibrutinib, Daratumumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Waldenstrom Macroglobulinaemia
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Given the tolerability and efficacy of ofatumumab in follicular lymphoma and Chronic Lymphocytic Leukemia, and the need to improve therapy for patients with WM utilizing a non-myelosuppressive agent this phase II trial of…
- Trial name
- NCT00811733
- Testing
- Ofatumumab
- Where
- 7 sites in United States
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline